166 related articles for article (PubMed ID: 38571688)
1. Sentinel Lymph Node Biopsy After Neoadjuvant Chemotherapy in cN0 Breast Cancer: Impact of HER2-Positive Status on Survival.
Alors-Ruiz J; Sanz-Viedma S; Fernández-Garcia FJ; Sendra-Portero F
Eur J Breast Health; 2024 Apr; 20(2):94-101. PubMed ID: 38571688
[TBL] [Abstract][Full Text] [Related]
2. Neoadjuvant chemotherapy and timing of sentinel lymph node biopsy in different molecular subtypes of breast cancer with clinically negative axilla.
Bi Z; Liu J; Chen P; Liu Y; Zhao T; Wang C; Zhang Z; Sun X; Qiu P; Cong B; Song X; Wang Y
Breast Cancer; 2019 May; 26(3):373-377. PubMed ID: 30666563
[TBL] [Abstract][Full Text] [Related]
3. Neo-adjuvant chemotherapy and axillary de-escalation management for patients with clinically node-negative breast cancer.
Shi ZQ; Qiu PF; Liu YB; Cong BB; Zhao T; Chen P; Wang CJ; Zhang ZP; Sun X; Wang YS
Breast J; 2019 Nov; 25(6):1154-1159. PubMed ID: 31332886
[TBL] [Abstract][Full Text] [Related]
4. Association of Low Nodal Positivity Rate Among Patients With ERBB2-Positive or Triple-Negative Breast Cancer and Breast Pathologic Complete Response to Neoadjuvant Chemotherapy.
Barron AU; Hoskin TL; Day CN; Hwang ES; Kuerer HM; Boughey JC
JAMA Surg; 2018 Dec; 153(12):1120-1126. PubMed ID: 30193375
[TBL] [Abstract][Full Text] [Related]
5. Update on sentinel lymph node biopsy after neoadjuvant chemotherapy in breast cancer patient.
Franceschini G; Di Leone A; Sanchez AM; D'Archi S; Terribile D; Magno S; Scardina L; Masetti R
Ann Ital Chir; 2020; 91():465-468. PubMed ID: 32312945
[TBL] [Abstract][Full Text] [Related]
6. Nodal Recurrence in Patients With Node-Positive Breast Cancer Treated With Sentinel Node Biopsy Alone After Neoadjuvant Chemotherapy-A Rare Event.
Barrio AV; Montagna G; Mamtani A; Sevilimedu V; Edelweiss M; Capko D; Cody HS; El-Tamer M; Gemignani ML; Heerdt A; Kirstein L; Moo TA; Pilewskie M; Plitas G; Sacchini V; Sclafani L; Tadros A; Van Zee KJ; Morrow M
JAMA Oncol; 2021 Dec; 7(12):1851-1855. PubMed ID: 34617979
[TBL] [Abstract][Full Text] [Related]
7. The nodal positivity rate in breast pCR patients with initially, clinically node-negative breast cancer after neoadjuvant systemic therapy: A systematic review and meta-analysis.
Ma L; Chen H; He J; Xie P; Gao P; Li Y; Zhang H; Fan Z
Front Oncol; 2023; 13():1167912. PubMed ID: 37064127
[TBL] [Abstract][Full Text] [Related]
8. Oncologic Safety of Sentinel Lymph Node Biopsy Alone After Neoadjuvant Chemotherapy for Breast Cancer.
Wong SM; Basik M; Florianova L; Margolese R; Dumitra S; Muanza T; Carbonneau A; Ferrario C; Boileau JF
Ann Surg Oncol; 2021 May; 28(5):2621-2629. PubMed ID: 33095362
[TBL] [Abstract][Full Text] [Related]
9. Axillary Staging After Neoadjuvant Chemotherapy for Breast Cancer: A Pilot Study Combining Sentinel Lymph Node Biopsy with Radioactive Seed Localization of Pre-treatment Positive Axillary Lymph Nodes.
Diego EJ; McAuliffe PF; Soran A; McGuire KP; Johnson RR; Bonaventura M; Ahrendt GM
Ann Surg Oncol; 2016 May; 23(5):1549-53. PubMed ID: 26727919
[TBL] [Abstract][Full Text] [Related]
10. Patterns of Axillary Management in Stages 2 and 3 Hormone Receptor-Positive Breast Cancer by Initial Treatment Approach.
Weiss A; Wong S; Golshan M; Freedman RA; Metzger O; Bellon J; Mittendorf EA; King TA
Ann Surg Oncol; 2019 Dec; 26(13):4326-4336. PubMed ID: 31562601
[TBL] [Abstract][Full Text] [Related]
11. Association of Tumor Molecular Subtype and Stage with Breast and Axillary Pathologic Complete Response After Neoadjuvant Chemotherapy for Breast Cancer.
Myers SP; Ahrendt GM; Lee JS; Steiman JG; Soran A; Johnson RR; McAuliffe PF; Diego EJ
Ann Surg Oncol; 2021 Dec; 28(13):8636-8642. PubMed ID: 34142288
[TBL] [Abstract][Full Text] [Related]
12. Toward omitting sentinel lymph node biopsy after neoadjuvant chemotherapy in patients with clinically node-negative breast cancer.
van der Noordaa MEM; van Duijnhoven FH; Cuijpers FNE; van Werkhoven E; Wiersma TG; Elkhuizen PHM; Winter-Warnars G; Dezentje V; Sonke GS; Groen EJ; Stokkel M; Vrancken Peeters MTFD
Br J Surg; 2021 Jun; 108(6):667-674. PubMed ID: 34157085
[TBL] [Abstract][Full Text] [Related]
13. How Often Does Neoadjuvant Chemotherapy Avoid Axillary Dissection in Patients With Histologically Confirmed Nodal Metastases? Results of a Prospective Study.
Mamtani A; Barrio AV; King TA; Van Zee KJ; Plitas G; Pilewskie M; El-Tamer M; Gemignani ML; Heerdt AS; Sclafani LM; Sacchini V; Cody HS; Patil S; Morrow M
Ann Surg Oncol; 2016 Oct; 23(11):3467-3474. PubMed ID: 27160528
[TBL] [Abstract][Full Text] [Related]
14. Management of the axilla in postmenopausal patients with cN0 hormone receptor-positive/HER2-negative breast cancer treated with neoadjuvant endocrine therapy and its prognostic impact.
Garcia-Tejedor A; Falo C; Fernandez-Gonzalez S; Laplana M; Gil-Gil M; Soler-Monso T; Martinez-Perez E; Calvo I; Calpelo H; Bajen MT; Benitez A; Ortega R; Petit A; Guma A; Campos M; Stradella A; Lopez-Ojeda A; Ponce J; Pla MJ; Pernas S
Breast Cancer Res Treat; 2023 Jun; 199(3):445-456. PubMed ID: 37043108
[TBL] [Abstract][Full Text] [Related]
15. Predicting Non-sentinel Lymph Node Metastases in Patients with a Positive Sentinel Lymph Node After Neoadjuvant Chemotherapy.
Barron AU; Hoskin TL; Boughey JC
Ann Surg Oncol; 2018 Oct; 25(10):2867-2874. PubMed ID: 29956095
[TBL] [Abstract][Full Text] [Related]
16. Real-world data on breast pathologic complete response and disease-free survival after neoadjuvant chemotherapy for hormone receptor-positive, human epidermal growth factor receptor-2-negative breast cancer: a multicenter, retrospective study in China.
Guan D; Jie Q; Wu Y; Xu Y; Hong W; Meng X
World J Surg Oncol; 2022 Sep; 20(1):326. PubMed ID: 36175898
[TBL] [Abstract][Full Text] [Related]
17. Sentinel lymph node biopsy before and after neoadjuvant chemotherapy in cN0 breast cancer patients: impact on axillary morbidity and survival-a propensity score cohort study.
Fernandez-Gonzalez S; Falo C; Pla MJ; Campos M; Ortega-Exposito C; Ortega R; Vicente M; Petit A; Bosch-Schips J; Bajen MT; Reyes G; Martínez E; González-Viguera J; Peñafiel J; Stradella A; Pernas S; Ponce J; Garcia-Tejedor A
Breast Cancer Res Treat; 2024 Apr; ():. PubMed ID: 38635082
[TBL] [Abstract][Full Text] [Related]
18. Omitting Sentinel Lymph Node Biopsy after Neoadjuvant Systemic Therapy for Clinically Node Negative HER2 Positive and Triple Negative Breast Cancer: A Pooled Analysis.
Alamoodi M; Wazir U; Mokbel K; Patani N; Varghese J; Mokbel K
Cancers (Basel); 2023 Jun; 15(13):. PubMed ID: 37444434
[TBL] [Abstract][Full Text] [Related]
19. Sentinel node biopsy after neoadjuvant chemotherapy in cytologically proven node-positive breast cancer.
Yagata H; Yamauchi H; Tsugawa K; Hayashi N; Yoshida A; Kajiura Y; In R; Matsuda N; Nakamura S
Clin Breast Cancer; 2013 Dec; 13(6):471-7. PubMed ID: 24267732
[TBL] [Abstract][Full Text] [Related]
20. Impact of Residual Nodal Disease Burden on Technical Outcomes of Sentinel Lymph Node Biopsy for Node-Positive (cN1) Breast Cancer Patients Treated with Neoadjuvant Chemotherapy.
Laws A; Hughes ME; Hu J; Barry WT; Dominici L; Nakhlis F; Barbie T; Duggan M; Weiss A; Rhei E; Carter K; Nimbkar S; Schnitt SJ; King TA
Ann Surg Oncol; 2019 Nov; 26(12):3846-3855. PubMed ID: 31222687
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
